A recent combined analysis of two phase 3 clinical trials has found that centanafadine, a unique norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), significantly reduces symptoms in adults with attention-deficit/hyperactivity disorder (ADHD). Centanafadine notably improved both hyperactivity/impulsivity and inattention symptoms within s…
